Forte Biosciences (FBRX) Convertible Debt (2016 - 2017)
Forte Biosciences (FBRX) reported Convertible Debt of $11.0 million for Q1 2017, up 224.19% quarter-over-quarter from $3.4 million in Q4 2016.
Forte Biosciences (FBRX) Convertible Debt (2016 - 2017) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Convertible Debt data on file, last reported at $11.0 million in Q1 2017.
- Convertible Debt for Q1 2017 came in at $11.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2017 was $11.0 million (changed N/A YoY), and the FY2016 annual result was $3.4 million, changed N/A from the prior year.
- Convertible Debt advanced to $11.0 million in Q1 2017 per FBRX's latest filing, from $3.4 million in the prior quarter.
- Over five years, Convertible Debt peaked at $11.0 million in Q1 2017 and troughed at $3.4 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 11.02 Mn |
| Dec 31, 2016 | 3.40 Mn |